Opposite effects on tumor growth depending on dose of Achyranthes bidentata polysaccharides in C57BL/6 mice

International Immunopharmacology

Volumn 7, Issue 5, 2007, Pages 568-577

  Jin, Li Qin ^a   Zheng, Zhao Jing ^a   Peng, Ying ^a   Li, Wei Xing ^a,b   Chen, Xiao Ming ^a   Lu, Jian Xin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Achyranthes bidentata polysaccharides (ABPS); Cell cycle; Cytokine; Lewis lung cancer (LLC); mRNA; NK

Indexed keywords

ACHYRANTHES BIDENTATA EXTRACT; INTERLEUKIN 6; MESSENGER RNA; POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; IN VIVO STUDY; LEWIS CARCINOMA; LOW DRUG DOSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN WEIGHT; TUMOR GROWTH; TUMOR VOLUME;

ACHYRANTHES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, LEWIS LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; ORGAN SIZE; POLYSACCHARIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPLEEN;

EID: 33947405149     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.12.009     Document Type: Article

References (31)

1. Hui Y.Z., Zou W., and Tian G.Y. Structural study on bioactive polysaccharide isolated (Abs) from the root of Achyranthes bidentata Blume. Acta Chem Sin 417 (1989) 621-622
2. Chen X.M., Xu Y.J., and Tian G.Y. Physical-chemical properties and structure elucidation of ABPS isolation from the root of Achyranthes bidenteta. Acta Pharm Sin 40 1 (2005) 32-35
3. Michels J.J., Marnay J., Plancoulaine B., and Chasle J. Flow cytometry in primary breast carcinomas: prognostic impact of S-phase fraction according to different analysis patterns. Cytom Part B (Clin Cytom) 59B (2004) 32-39
4. Piriou L., Chilmonczyk S., Genetet N., and Albina E. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T lymphocyte activity in human and in different animal species. Cytometry 41 (2000) 289-297
5. Liu J.J., Huang T.S., Hsu M.L., Chen C.C., Lin W.S., Lu F.J., et al. Antitumor effects of the partially purified polysaccharides from Antrodia camphorata and the mechanism of its action. Toxicol Appl Pharmacol 201 (2004) 186-193
6. Xiang D.-B., and Li X.-Y. Antitumor activity and immuno-potentiating actions of Achyranthes bidentata polysaccharides. Acta Pharmacol Sin 6 (1993) 556-581
7. Li Z.K., and Li D.D. The immunomodulativatory effect of Achyranthes bidentata polysaccharides. Acta Pharm Sin 32 (1997) 881-887
8. Leibovici J., Kopel S., Siegal A., and Gal-Mor O. Effect of tumor inhibitory and stimulatory doses of levan, alone and in combination with cyclophosphamide, on spleen and lymph nodes. Int J Immunopharmacol 8 (1986) 391-403
9. Leibovici J., Kopel S., and Wolman M. Opposite effects on tumor growth depending on dose of an immunomodulatory polysaccharide with or without cyclophosphamide. Anticancer Res 5 (1985) 553-558
10. Sherr C.J. Cancer Cell Cycles. Science 274 (1996) 1672-1677
11. Lin S.B., Li C.H., Lee S.S., and Kan L.S. Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci 72 (2003) 2381-2390
12. Li G., Kim D.H., Kim T.D., Park B.J., Park H.D., Park J.I., et al. Protein-bound polysaccharide from Phellinus linteus induces G2/M phase arrest and apoptosis in SW480 human colon cancer cells. Cancer Lett 216 (2004) 175-181
13. Bae J.S., Jang K.H., Yim H., and Jin H.K. Polysaccharides isolated from Phellinus gilvus inhibit melanoma growth in mice. Cancer Lett 218 (2005) 43-52
14. Hirano T., and Kishimoto T. Interleukin-6. In: Sporn M.B. (Ed). Handbook of Experimental Pharmacology vol. 95 (1990), Springer-Verlag, Berlin Heidelberg 633-665
15. Akira S., Taga T., and Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 54 (1993) 1-78
16. Ueda T., Shimada E., and Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29 (1994) 423-429
17. Takeda K., Fujii N., Nitta Y., Sakihara H., Nakayama K., Rikiishi H., et al. Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6. Jpn J Cancer Res 82 (1991) 1299-1308
18. Komoda H., Tanaka Y., Honda M., Matsuo Y., Hazama K., and Takao T. Interleukin-6 levels in colorectal cancer tissues. World J Surg 22 (1998) 895-898
19. Bihl M., Tamm M., Nauck M., Wieland H., Perruchoud A.P., and Roth M. Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 19 (1998) 606-612
20. Yamaji H., Iizasa T., Koh E., Suzuki M., Otsuji M., Chang H., et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 53 (2004) 786-792
21. Ashizawa T., Okada R., Suzuki Y., Takagi M., Yamazaki T., Sumi T., et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8 (2005) 124-131
22. Fu J., Zheng J., Fang W., and Wu B. Effect of interleukin-6 on the growth of human lung cancer cell line. Chin Med J 111 (1998) 265-268
23. Adler H.L., McCurdy M.A., Kattan M.W., Timme T.L., Scardino P.T., and Thompson T.C. Elevated levels of circulating inteleukin-6 and transforming growth factor-b1 in patients with metastatic prostatic carcinoma. J Urol 161 (1999) 182-187
24. Nakashima J., Tachibana M., Horiguchi Y., Oya M., Ohigashi T., Asakura H., et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 (2000) 2702-2706
25. Tanner J., and Tosato G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 88 (1991) 239-247
26. Horie T., Dobashi K., Iizuka K., Yoshii A., Shimizu Y., Nakazawa T., et al. Interferon-gamma rescues TNF-alpha-induced apoptosis mediated by up-regulation of TNFR2 on EoL-1 cells. Exp Hematol 27 (1999) 512-519
27. Lewis G.D., Aggarwal B.B., Eessalu T.E., Sugarman B.J., and Shepard H.M. Modulation of the growth of transformed cells by human tumor necrosis factor-alpha and interferon-gamma. Cancer Res 47 (1987) 5382
28. Kimura K., Bowen C., Spiegel S., and Gelmann E.P. TNF - αsensitizes prostate cancer cells to gamma-irradiation induced apoptosis. Cancer Res 59 (1999) 1606-1614
29. Volland S., Amtmann E., and Sauer G. TNF accelerates the S-phase of the cell cycle in tumor cells. Int J Cancer 56 (1994) 698-705
30. Wu S., Boyer C.M., Whitaker R.S., Berchuck A., Wiener J.R., Weinberg J.B., et al. Tumor necrosis factor - α as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor - α expression. Cancer Res 53 (1993) 1939-1944
31. Montesano R., Soulie P., Eble J.A., and Carrozzino F. Tumour necrosis factor {alpha} confers an invasive, transformed phenotype on mammary epithelial cells. J Cell Sci 118 (2005) 3487-3500